Clinical Trials

  • The Breathe Easy Early ORBEX Study is a three -year study to identify if a daily capsule of Broncho-Vaxom may help prevent or delay young children from developing wheezing or asthma- like symptoms. Other studies have found that Broncho-Vaxom can help prevent upper respiratory infections and stimulate immune defenses, and has been safely and effectively used around the world. Broncho-Vaxom has not been approved yet in the United States however, it has been used safely by 43 million children in countries all over the world.
  • The purpose of this study is to determine the incidence and severity of acute GVHD following CD34+ selection in children, adolescents and young adults receiving an allogeneic peripheral blood stem cell transplant from a family member or unrelated adult donor for a malignant condition.
  • The reason for this nationwide study is to help us learn if treatment with German cockroach extract, given as allergy shots, given along with standard asthma care makes children less likely to have asthma symptoms. The study will take up to 36 months. Study visits will include questionnaires, a physical examination, an allergy skin test, breathing tests, and blood, nasal collections, and allergy shots. You will be reimbursed for each completed study visit and your child will receive a gift.
  • Several children are born with birth defects every day. Through extensive genetic research, we have learned over the years that there are genetic factors that can contribute to the occurrence of some of these defects, especially in children with more than one congenital defect. However, the underlying genetic causes of many birth defects still remain unknown. The goal of this study is to use a sophisticated technology called whole exome/genome sequencing to identify underlying genetic causes of surgical birth defects.
  • CARE is a new research initiative that aims to investigate the underlying genetic causes of various birth defects. By identifying the cause of these defects, we hope to be able to better understand their natural history which may ultimately lead to better treatment and management. Knowing the genetic causes of birth defects also allows us to assess the hereditary risk of the defect in a family. The study is free and involves submission of a blood or saliva sample from a child with a birth defect and both parents.
  • Each year more than 1,000 babies in the United States are born with a Congential Diaphragmatic Hernia (CDH). For the majority of these babies, the cause of the CDH is unknown. DHREAMS (Diaphragmatic Hernia Research & Exploration; Advancing Molecular Science) study was created to improve the understanding of the molecular genetic basis of CDH. This National Institute of Health (NIH)-funded research team is composed of health care providers and researchers across the country, coordinated at Columbia University Medical Center.
  • We are recruiting boys between 3-9 years old and girls between 3-8 years old to participate in a research study. Children who would like to participate must be healthy and not showing signs of puberty. The goal of the study is to understand the relationship between early body development, metabolism (sugars and fats processing), and the saliva microbiome (bacteria that normally live inside the body). The study is performed in the morning after an overnight fast and may be completed in less than 2 hours.
  • We are recruiting boys between 3-9 years old and girls between 3-8 years old to participate in a research study. Children who would like to participate must be healthy and not showing signs of puberty. The goal of the study is to understand the relationship between early body development, metabolism (sugars and fats processing), and the saliva microbiome (bacteria that normally live inside the body). The study is performed in the morning after an overnight fast and may be completed in less than 2 hours.
  • The purpose of this study is to see if the use of bubble nasal continuous positive airway pressure (NCPAP) at a pressure of 6-7 centimeters of water (cm H2O) in very low birth weight (VLBW) infants is associated with improved gas exchange without any related changes in vital signs.
  • The main purpose of this study is to see if eribulin might work and might be used in the treatment of pediatric subjects with rhabdomyosarcoma (RMS), non-rhabdomyosarcoma soft tissue sarcoma (NRSTS) and Ewing sarcoma (EWS) that has either come back or has not responded to the standard therapy. Eribulin will be administered as an intravenous (IV) infusion on Days 1 and 8 of each 21-day cycle.

Pages